Biotech Business - June 25, 2020
Camurus announces stronger than expected sales during the first half of 2020
Camurus has announced revised full year 2020 guidance for the company’s revenue and product sales. Camurus’ guidance for net revenue is increased to SEK 340–380 million from SEK 290–330 million with estimated product sales of SEK 310–340 million, previously SEK 240–280 million. The improvements are driven by increasing market shares of Buvidal for treatment of […]
Drug Development Pharma - October 2, 2017
EMA Validation for Camurus
The company’s marketing authorization application (MAA) for the investigational, weekly and monthly CAM2038 buprenorphine depots for the treatment of opioid dependence has been fully validated by the European Medicines Agency. The application, submitted on 26 July 2017, is now under assessment by the Committee for Human Medicinal Products (CHMP). “The validation of the MAA for CAM2038 […]
Clinical Trials - August 7, 2017
Camurus and Braeburn Pharmaceuticals announces Phase 2 results
Braeburn Pharmaceuticals and Camurus has announced positive results from a Phase 2 pharmacokinetic study of weekly and monthly buprenorphine (CAM2038) depots in opioid dependent patients with moderate-to-severe non-cancer chronic pain. A total of 65 participants were enrolled and received one of three doses of CAM2038 after being transitioned from sublingual buprenorphine. The primary study objective […]
Clinical Trials - May 2, 2017
Camurus announces positive clinical trial results
Braeburn Pharmaceuticals and Camurus announces positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 in patients with moderate-to-severe opioid use disorder. “The positive results from this study, coupled with the earlier reported positive results from the pivotal Phase 3 efficacy trial, enable our teams to finalize regulatory submissions […]
Collaboration - February 8, 2017
Two new Swedish industry research centres with life science focus
The Swedish Foundation for Strategic Research (SSF) is investing 400 million SEK in four industrial research centres, and two of these are focusing on challenges within life science; nucleotide based drugs and personalized diabetes medicine. SSF has decided to establish four industry research centres with the purpose to enable groundbreaking innovation coming from external industrial challenges. […]
Agreement - January 1, 2016
Camurus in agreement with Rhythm
The two companies have entered a license agreement for the use of Camurus’ drug delivery technology, FluidCrystal, to formulate setmelanotide (RM-493), Rhythm’s novel melanocortin-4 receptor (MC4R) agonist. Under the terms of the agreement, Camurus has granted Rhythm a worldwide license to the FluidCrystal technology to formulate setmelanotide and to develop, manufacture, and commercialize this new […]
